Celiac disease, an autoimmune disorder that affects about 1 percent of the U.S. population, is triggered by the ingestion of wheat and related cereals in genetically susceptible individuals. The immune response results in inflammation and tissue damage in the small intestine, which can lead to severe gastrointestinal symptoms, as well as a number of extra-intestinal manifestations. Gluten proteins, which represent about 75 percent of the total protein content of wheat grain, are known to be the primary triggers of the immune response in celiac disease. While the role of gluten in celiac disease has been extensively studied since the 1950s, the possible involvement of wheat non-gluten proteins has not been characterized and is poorly understood.
“This work is the first to attempt mapping of the B cell response to non-gluten proteins of wheat in celiac disease,” said the study’s principal investigator, Armin Alaedini, PhD, assistant professor of medicine (in the Institute of Human Nutrition and the Celiac Disease Center) at Columbia University.
Dr. Alaedini and postdoctoral fellows Sina Huebener and Melanie Uhde, in collaboration with a team of scientists at the U.S. Department of Agriculture, searched for the protein targets through two-dimensional separation techniques, immunoassays, and mass spectrometry. The new data identify a group of molecules known as serpins, in addition to four other types of wheat protein, as novel non-gluten immunogenic proteins in celiac disease.
Co-author Peter H. R. Green, MD, the Phyllis and Ivan Seidenberg Professor of Medicine and director of the Celiac Disease Center at Columbia University Medical Center, said, “These results indicate that immunologic reactivity in celiac disease may not be limited to wheat gluten, but can involve certain non-gluten proteins, too. I think the findings have implications for understanding the mechanism of the disease and developing new therapeutics.”
The authors caution that it remains to be seen whether the identified proteins play a role in contributing to the intestinal damage in patients with celiac disease. Dr. Alaedini noted that, “Although we can’t draw direct conclusions about the pathogenic effects of the proteins yet, these findings should prompt a closer look into their potential involvement in the inflammatory processes at work in celiac disease.”
This research was supported by the National Center for Advancing Translational Sciences, NIH (UL1 TR000040).
The authors report no financial or other conflicts of interest.
Celiac Disease Center at Columbia University provides comprehensive medical care for adults and pediatric patients with celiac disease, including nutrition and attention to the multiple associated conditions that occur in celiac disease. The center is involved in the care of thousands of patients with celiac disease and gluten sensitivity, providing better access to proper testing, diagnosis, treatment, and follow-up care. Additional information is available at http://www.celiacdiseasecenter.columbia.edu/.
Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit cumc.columbia.edu or columbiadoctors.org.